Want to Subscribe?
Read Corporate India and add to your Business Intelligence

Unlock Unlimited Access
Published: May 31, 2025
Updated: May 31, 2025
BSE ticker code | 504918 |
NSE ticker code | SANDUMA |
Major activity | Coal |
CMD | Rhoniparambil R. Raghunandan |
Equity capital | Rs 162.04 crore; FV Rs 10 |
52 week high/low | Rs 637 / Rs 338 |
CMP | Rs 481.05 |
Market Capitalisation | Rs 7794.69 crore |
Recommendation | Buy |
Sandur Manganese & Iron Ores, the flagship com pany of the Karnataka-based Sandur group, is involved in the mining of low-phosphorus manganese and iron ore in the Hosapete-Ballari region of Karnataka. It is one of India’s highly integrated and diversified commodity producers, with a rich heritage and over six and a half decades of experi ence in systematic, safe and scien tific mining. Established in 1954, the company has since expanded from mining operations to the production of ferro alloys, cokes and energy, and continues to work towards further downstream expansion and diversi fication. Marching ahead with its core values of integrity and ethics, the company focuses on sustainable de velopment, environmental protec tion, social impact and innovation.
Sandur Manganese has a pro duction capacity of 0.46 mtpa of manganese ore, 3.8 mtpa of iron ore, 0.5 mtpa of coke, 32 MW/power, 0.125 mtpa of FeMn, 0.095 SIMn/0.135 mtpa of pig iron and 0.050 mtpa of FeSi. It has estimated reserves of 17 mt of manganese ore. Today, the company is the third largest manganese ore miner in India with a mining area spread over 1,999 hectares. It is widely respected for its heritage of trust, integrity and scientific advancement. In short, the company has the largest private sector manga nese ore mines in the country producing the finest low grade, low- phosphorus manganese required to manufacture ferro alloy and steel.
Sandur Manganese has made rapid strides on the finan cial front. During the last 15 years, its sale turnover has ex panded multiple times from Rs. 363 crore in the fiscal year 2011 to Rs. 3135 crore in fiscal year 2025, with operating profit shooting up more than 5 times from Rs 140 crore to Rs 785 crore and the profit at net level spurting over 5 times from Rs. 83 crore to Rs 471 crore. What is more, its prospects going ahead are all the more promising. Consider:
PERFORMANCE INDICATORS (Rs. in crore)
Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) |
---|---|---|---|---|---|
2023-24 | 8171.16 | 18.00 | -- | -- | 59.80 |
2024-25 (E) | 9151.18 | 91.13 | 0.70 | 1.0 | 61.30 |
2025-26 (E) | 1024.40 | 110.52 | 2.10 | 1.0 | 63.35 |
BSE ticker code | 543635 |
NSE ticker code | PPLPHARMA |
Major activity | Pharmaceuticals |
Chairman | Nandini Piramal |
Equity capital | Rs 1323.58 crore; FV Rs 10 |
52 week high/low | Rs 308 / Rs 135 |
CMP | Rs 206.30 |
Market Capitalisation | Rs 27422.39 crore |
Recommendation | Buy |
Piramal Pharma (PPL) is a part of the Ajay Piramal group, a business conglomerate with diverse interests in financial services, real estate and pharma, among others. PPL offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global development and manufacturing facilities and has a global distribution net work. It includes Piramal Pharma Solutions (PPS), an integrated con tract development and manufactur ing organisation, Piramal Critical Care (PCC), a complex hospital ge nerics business, and India Con sumer Healthcare, which sells over the-counter products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Pvt Ltd a JV with Abbvie Inc — has emerged as one of the market leaders in the ophthalmology therapy area. Furthermore, PPL has a mi nority investment in Yapan Bio Pvt Ltd.
The Ajay Piramal group was one of the largest players in the pharma sector, with its flagship company, Piramal Healthcare, created by taking over some foreign companies operating in India, including Nicholas and Roche Products. In 2010, the group sold its domestic pharma business to Abbot but re-entered the pharma business five years ago by setting up Piramal Pharma. The company has made good progress, with its sales turnover rising from Rs 6,315 crore in fiscal 2021 to Rs 9,151 crore in fiscal 2025, and its oper ating profit, which went down from Rs 1,428 crore in fiscal 2021 to Rs 629 crore in fiscal 2023, swiftly recovering to Rs 1,445 crore in fiscal 2025. On the net profit front, after earn ing a net profit of Rs 835 crore in fiscal 2021, the company plunged into the red, incurring a loss of Rs 186 crore in fiscal 2023, but recovered to show a net profit of Rs 91 crore in fiscal 2025. What is more, prospects for the company going ahead are quite healthy. Consider:
PERFORMANCE INDICATORS (Rs. in crore)
Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) |
---|---|---|---|---|---|
2023-24 | 2356.74 | 192.02 | 31.70 | 350.0 | 194.10 |
2024-25 (E) | 2456.40 | 195.10 | 32.40 | 350.0 | 196.40 |
2025-26 (E) | 2630.75 | 199.45 | 34.60 | 375.0 | 199.45 |
BSE ticker code | 531120 |
NSE ticker code | PATELENG |
Major activity | Civil Construction |
Chairman | Janky Rupen Patel |
Equity capital | Rs 84.44 crore; FV Re 01 |
52 week high/low | Rs 75 / Rs 33 |
CMP | Rs 40.26 |
Market Capitalisation | Rs 3399.46 crore |
Recommendation | Buy |
Mumbai-headquartered Patel Engineering, over seven decades old, is a leading infrastructure and construc tion services company with a PQ (pre- qualification) in con struction work in the infrastructure segment like dams, tun nels, hydro-electric projects, irrigation projects, roads, high ways, bridges, railways, refineries, real estate and townships. It has successfully completed over 250 projects, including 87+ dams, 15,000+ MWh hydro-electric projects and 1,200 km+ roads. At present, it has a marketshare of over 45 per cent in under- construction hydro-electric plants in India. The company has also executed projects in Indonesia, Singapore, Nepal and Mauritius.
Key projects executed by the company include the 520 MW Tapovan hydro-electric project, the 412 MW Rampur hydro plant, the 800 MW Parbati hydro, and the 600 MW Kameng project.
Patel Engineering’s financial performance is healthy de spite some challenging situations, including the sudden death of Chairman and Managing Director Rupen Patel. The sales turnover during the last 12 years has expanded from Rs 3,701 crore in fiscal 2014 to Rs 5,093 crore in fiscal 2025, with operating profit moving up from Rs 467 crore to Rs 733 crore and the profit at net level shooting up almost 10 times from Rs 25 crore to Rs 248 crore. Going ahead, though the short-term prospects are challenging, the long-term outlook is strong. Consider:
PERFORMANCE INDICATORS (Rs. in crore)
Year | Net Series | Net Profit | EPS (Rs.) | Div (%) | BV (%) |
---|---|---|---|---|---|
2023-24 | 4544.11 | 234.47 | 2.46 | -- | 43.20 |
2024-25 (E) | 5093.36 | 349.35 | 4.10 | -- | 44.80 |
2025-26 (E) | 5235.40 | 368.53 | 5.15 | -- | 46.15 |
June 30, 2025 - Combined Issue
Industry Review
Want to Subscribe?
Read Corporate India and add to your Business Intelligence
Unlock Unlimited Access
Lighter Vein
Popular Stories
Archives